Overview
- Confirmed price bands set starter or oral doses at about $149 per month pending FDA approvals, government pricing at roughly $245, and TrumpRx injectables initially near $350 trending to $245 within two years.
- Medicare will run a mid‑2026 Part D pilot with a $50 monthly copay for eligible patients, covering about 10% of beneficiaries across three defined clinical cohorts.
- TrumpRx.gov is slated to launch in January 2026 to sell discounted GLP‑1 prescriptions directly to consumers outside insurance.
- States can opt in to the $245 monthly Medicaid pricing for covered uses, while the impact on private insurers and total program costs remains unresolved.
- Eli Lilly and Novo Nordisk receive concessions reported to include tariff relief and expedited FDA review vouchers in exchange for the pricing commitments.